



LKT Laboratories, Inc.

Bicalutamide

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B3209

CAS No. 90357-06-5

Chemical Name N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+)- Propanamide

Synonym Casodex

Formula C₁₈H₁₄F₄N₂O₄S

Formula Wt. 430.37

Melting Point 191-193 °C


Purity ≥98%

Solubility Soluble in acetone, DMSO (86mg/m), ethanol (7 mg/mL) or THF. Slightly soluble in chloroform or ether. Practically insoluble in water.

Store Temp Ambient

Ship Temp Ambient

Description Bicalutimide is an inhibitor of the androgen receptor that exhibits anticancer chemotherapeutic activity. With other anti-androgens, bicalutimide decreases levels of Bcl-2, Bcl-XL, caspase-3, and PARP, induces apoptosis, and inhibits cell growth of prostate cancer cells. In similar animal models, this compound decreases plasma PSA levels and suppresses tumor growth. Bicalutamide binds the androgen receptor in two sites, distorting coactivator binding and inhibiting transcription.



Bulk quantities available upon request

Product ID	Size
B3209	100 mg
B3209	250 mg
B3209	1 g

References Squillace RM, Miller D, Wardwell SD, et al. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. *Int J Oncol.* 2012 Aug;41(2):425-32. PMID: 22614157.

Yan J, Xie B, Capodice JL, et al. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. *Prostate.* 2012 Feb;72(3):244-52. PMID: 21656835.

De Amicis F, Thirugnansampanthan J, Cui Y, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. *Breast Cancer Res Treat.* 2010 May;121(1):1-11. PMID: 19533338.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.